TrialNature medicine2023

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Hatem Soliman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.